Exclusion Criteria:~* Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With
Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate
Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)
